RT Generic
T1 Left ventricular assist device.
A1 Jiménez-Navarro, Manuel
A1 Molero, Encarnación
A1 Teresa, Eduardo de
K1 Inhibidores de la enzima convertidora de angiotensina
K1 Insuficiencia cardíaca
K1 Corazón Auxiliar
K1 Antagonistas Adrenérgicos beta
K1 Espironolactona
AB To the Editor:The value of angiotensin-converting–enzyme (ACE) inhibitors, beta-blockers, and spironolactone has been well established by the results of numerous clinical trials. About 70 percent of the patients described by Rose et al. were treated with ACE inhibitors or angiotensin II–receptor antagonists; 35 to 40 percent received spironolactone, and only about 20 percent received beta-blockers. Thus, this population cannot have been considered to be optimally treated from the point of view of medical therapy.
PB Massachusetts Medical Society
SN 0028-4793
YR 2002
FD 2002-03-28
LK http://hdl.handle.net/10668/2053
UL http://hdl.handle.net/10668/2053
LA en
NO Jiménez-Navarro M, Molero E, Teresa E de. Left ventricular assist device. N. Engl. J. Med.. 2002; 346(13):1023-5; author reply 1023-5
DS RISalud
RD Apr 11, 2025